NCT05407909招募中1 期
To Evaluate the Safety and Tolerability of SYHX2001 in Patients With Advanced or Metastatic Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.1 个研究点 分布在 1 个国家目标入组 176 人开始时间: 2022年7月27日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 176
- 试验地点
- 1
- 主要终点
- Dose limiting toxicities (DLT) in stage Ⅰ
研究概览
简要总结
This is a Phase 1, open-label, multicenter, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the experimental drug(SYHX2001) in previously treated patients with advanced or metastatic cancer.
详细描述
This is a multicenter, open-label, dose-escalation, dose-expansion Phase 1 study of SYHX2001(name of the experimental drug) in patients with advanced or metastatic cancers who have exhausted standard treatment. The study will consist of 2 parts, a dose escalation part and a cohort expansion part. Once the recommended phase 2 dose (RP2D) has been determined in the dose escalation part, a cohort expansion part involving up to three separate cohorts will be conducted. For patients, the study will include a screening phase, a treatment phase, and a post treatment follow-up phase. An end-of-study visit will be conducted within 30 days after the last dose of SYHX2001.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients with an age of 18~75years (inclusive).
- •Confirmed histologic or cytologic diagnosis of an advanced and/or metastatic solid tumor.
- •At least one measurable lesion as defined by RECIST version 1.
- •Eastern Cooperative Oncology Group Performance Status 0 or
- •Life expectancy ≥3 months.
- •Major organ function within 14 days prior to treatment meets the following criteria (no blood transfusion, Erythropoietin(EPO), Granulocyte Colony Stimulating Factor(G-CSF) or other medical support): Absolute Neutrophil Count(ANC)≥1.5×10^9/L，Platelet(PLT)≥90×10^9/L，Hemoglobin(Hb)≥100g/L or≥6.2 mmol/L；Creatinine(Cr)≤1.5×upper limit of normal(ULN) and creatinine clearance rate≥50mL/min；Total Bilirubin(TBIL)≤1.5×ULN; Prothrombin time(PT)≤1.5×ULN , Activated Partial Thromboplastin Time(APTT)≤1.5×ULN , Aspartate Aminotransferase(AST)/Alanine Aminotransferase(ALT)≤2.5 × ULN.
- •Signed informed consent form.
排除标准
- •Chemotherapy, radiotherapy, biotherapy, endocrine therapy, targeted therapy, immunotherapy and other anti-tumor treatment within 4 weeks prior to the first dose of the study drug, or administration of other investigational agents within 4 weeks or 5 half-lives prior to the first dose of the study drug, whichever is longer.
- •Major surgery or significant trauma within 4 weeks prior to the first dose of the study drug.
- •Adverse reactions from the previous anti-tumor treatment have not yet recovered to ≤ level 1 based on CTCAE 5.0。
- •Have a history of severe cardiovascular and cerebrovascular disease.
- •Central nervous system metastasis or meningeal metastasis with clinical symptoms, or other evidence shows that the patient's central nervous system metastasis or meningeal metastasis has not been controlled and not suitable for the study according to the judgment of the investigator.
- •Known history of hypersensitivity to test drug components.
- •Patients with recent active bleeding or a history of bleeding.
- •Those with coagulation disorders or taking thrombolytic, anticoagulant or antiplatelet agglutination drugs.
- •Gastrointestinal perforation, abdominal fistula, or intra-abdominal abscess within 6 months prior to first dose; or currently under investigator's judgement there are high risk factors for hollow organ perforation/fistula formation).
- •Inability to swallow the drug orally, or a condition that seriously affects gastrointestinal absorption in the judgment of the investigator.
- •Irritable bowel syndrome with signs/symptoms requiring medication.
- •Persistent active diarrhea requiring medical treatment.
- •Concomitant use of strong CYP3A4 inhibitors or inducers, strong CYP2D6 inhibitors and strong P-gp inhibitors within 14 days prior to the first dose of the study drug.
- •History of autoimmune diseases, immunodeficiency, including HIV positive, or other acquired, congenital immunodeficiency, or organ transplant history.
- •Known Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), or other active viral infection.
- •Male and female patients of childbearing potential do not agree to use suitable method of contraception during the treatment and 6 months after the last dose of study medication; female patients do not have negative results of serum/urine pregnancy test within 7 days prior to enrollment and would be breastfeeding.
- •Not suitable for this study as determined by the investigator due to other reasons.
研究组 & 干预措施
SYHX2001
Experimental
SYHX2001 will be administered orally.
干预措施: SYHX2001 (Drug)
结局指标
主要结局
Dose limiting toxicities (DLT) in stage Ⅰ
时间窗: Baseline through Day 28
Maximum tolerated dose (MTD) in stage Ⅰ
时间窗: Baseline through Day 28
Overall response rate (ORR) in stage Ⅱ
时间窗: Up to approximately 2 years
Recommended phase 2 dose (RP2D)
时间窗: Baseline through approximately 2 years
Incidence and severity of adverse events in stage Ⅰ
时间窗: Baseline through approximately 2 years
次要结局
- PFS Progression-free survival (PFS)(up to approximately 2 years)
- Change from Baseline in symmetrical arginine dimethylation (SDMA) as a pharmacodynamics(PD) measure(Baseline and up to approximately 2 years)
- Maximum observed plasma concentration (Cmax) of SYHX2001(Baseline and up to approximately 2 years)
- Area under the plasma concentration-time curve (AUC) extrapolated from time zero to infinity (AUC[0-inf]) of SYHX2001(up to approximately 2 years)
- AUC from time zero to the last quantifiable concentration after dosing (AUC[0-t]) of SYHX2001(up to approximately 2 years)
- Terminal phase half-life (t1/2) of SYHX2001(up to approximately 2 years)
- Oral clearance (CL/F) of SYHX2001(up to approximately 2 years)
- Duration of Response (DOR)(up to approximately 2 years)
- Number of patients with any adverse events(AEs) and serious adverse events(SAEs) in stage Ⅱ(up to approximately 2 years)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORSAdvanced Solid TumorsNCT05277168Jiangsu HengRui Medicine Co., Ltd.83
招募中
1 期
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMMLMyelodysplastic SyndromesChronic Myelomonocytic LeukemiaAcute Myeloid LeukemiaNCT05641259Guangzhou Lupeng Pharmaceutical Company LTD.198
已完成
1 期
A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid TumorsSolid TumorNon Small Cell Lung CancerPapillary Thyroid CancerColorectal AdenocarcinomaOvarian CancerPancreatic CancerMelanomaNCT04731467Famewave Ltd.79
尚未招募
1 期
A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic MalignanciesMultiple MyelomaLymphomaAcute Myeloid LeukemiaNCT05055791CSPC ZhongQi Pharmaceutical Technology Co., Ltd.312
终止
1 期
Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid TumoursAdvanced Solid TumorNCT05255484LaNova Medicines Limited24